Jafari Atefeh, Khalili Hossein, Dashti-Khavidaki Simin
Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Enghelab Ave., P.O. Box 14155/6451, Tehran, 1417614411, Iran.
Eur J Clin Pharmacol. 2014 Sep;70(9):1029-40. doi: 10.1007/s00228-014-1712-z. Epub 2014 Jun 25.
In this study, data regarding epidemiology, risk factors, pathogenesis and outcome of tenofovir-induced nephrotoxicity will be reviewed, and current and future approaches for prevention will be discussed.
The data were collected by searching Scopus, PubMed, Medline, Science direct, Clinical trials and Cochrane database systematic reviews. The keywords used as search terms were "Tenofovir", "TDF", "NRTI", "Nephrotoxicity", "Renal failure", "Kidney damage", "HIV" and "AIDS".
Several predisposing factors including elevated baseline SCr, concomitant nephrotoxic medications, low body weight, advanced age, tenofovir disoproxil fumarate (TDF) dose and duration of treatment and lower CD4 cell count were identified as risk factors for development of TDF-induced nephrotoxicity. Cellular accumulation through increased entry from the human organic anion transporters and decreased efflux into tubular lumen is main mechanism of nucleotide analogue antiviral induced nephrotoxicity. Renal function assessment and monitoring at baseline and during TDF treatment are the main approach of prevention of TDF-induced nephrotoxicity. Rosiglitazone may be helpful in patients presenting with TDF-induced nephrotoxicity. Pretreatment with melatonin prevented all known histological changes in proximal tubular mitochondira induced by TDF. Use of antioxidants with mitochondria-targeted properties such as MitoQ or Mito-CP may prevent proximal tubular mitochondrial against TDF damage. Vitamin E, ebselen, lipoic acid, plastoquinone, nitroxides, SOD enzyme mimetics, Szeto-Schiller (SS) peptides, and quercetin are other potential agents for prevention of TDF-induced nephrotoxicity. However, data regarding effectiveness of nephroprotective agents against TDF-induced nephrotoxicity are not conclusive. Before extrapolation of the preclinical evidence to clinical practice, these evidence should be confirmed in future human studies.
本研究将回顾有关替诺福韦所致肾毒性的流行病学、危险因素、发病机制及转归的数据,并讨论当前及未来的预防方法。
通过检索Scopus、PubMed、Medline、Science direct、临床试验和Cochrane数据库系统评价来收集数据。用作检索词的关键词为“替诺福韦”“TDF”“核苷类逆转录酶抑制剂”“肾毒性”“肾衰竭”“肾损伤”“HIV”和“艾滋病”。
包括基线血清肌酐升高、同时使用肾毒性药物、低体重、高龄、富马酸替诺福韦二吡呋酯(TDF)剂量及治疗持续时间以及较低的CD4细胞计数等几个易感因素被确定为TDF所致肾毒性发生的危险因素。通过人类有机阴离子转运体增加摄入及减少向肾小管腔外排导致的细胞内蓄积是核苷酸类似物抗病毒药物所致肾毒性的主要机制。在基线及TDF治疗期间进行肾功能评估和监测是预防TDF所致肾毒性的主要方法。罗格列酮可能对出现TDF所致肾毒性的患者有帮助。褪黑素预处理可预防TDF诱导的近端肾小管线粒体所有已知的组织学变化。使用具有线粒体靶向特性的抗氧化剂如MitoQ或Mito-CP可能预防近端肾小管线粒体免受TDF损伤。维生素E、依布硒啉、硫辛酸、质体醌、氮氧化物、超氧化物歧化酶模拟酶、司徒-席勒(SS)肽和槲皮素是预防TDF所致肾毒性的其他潜在药物。然而,关于肾保护剂预防TDF所致肾毒性有效性的数据尚无定论。在将临床前证据外推至临床实践之前,这些证据应在未来的人体研究中得到证实。